It has been described in prostate cancer stem cells [24], and with an enhanced effect when trabectedin is administered in combination with other drugs like PARP1 inhibitors in sarcoma [25] or campthotecin in sarcoma models [26]. The gene discussed is PARP1; the disease is prostate carcinoma.